X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES TORRENT PHARMA ALKEM LABORATORIES/
TORRENT PHARMA
 
P/E (TTM) x - 45.0 - View Chart
P/BV x 6.9 6.4 109.4% View Chart
Dividend Yield % 0.6 0.8 77.3%  

Financials

 ALKEM LABORATORIES   TORRENT PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
TORRENT PHARMA
Mar-18
ALKEM LABORATORIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,550 102.5%   
Low Rs1,2321,144 107.7%   
Sales per share (Unadj.) Rs417.5354.7 117.7%  
Earnings per share (Unadj.) Rs56.340.1 140.5%  
Cash flow per share (Unadj.) Rs64.764.2 100.8%  
Dividends per share (Unadj.) Rs12.7014.00 90.7%  
Dividend yield (eoy) %0.91.0 86.6%  
Book value per share (Unadj.) Rs292.9273.1 107.2%  
Shares outstanding (eoy) m119.57169.22 70.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.8 89.0%   
Avg P/E ratio x25.133.6 74.6%  
P/CF ratio (eoy) x21.821.0 103.9%  
Price / Book Value ratio x4.84.9 97.7%  
Dividend payout %22.634.9 64.6%   
Avg Mkt Cap Rs m168,653227,897 74.0%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m9,17111,353 80.8%   
Avg. sales/employee Rs ThNM4,083.0-  
Avg. wages/employee Rs ThNM772.3-  
Avg. net profit/employee Rs ThNM461.3-  
INCOME DATA
Net Sales Rs m49,91560,021 83.2%  
Other income Rs m1,6452,988 55.0%   
Total revenues Rs m51,56163,009 81.8%   
Gross profit Rs m8,48213,493 62.9%  
Depreciation Rs m1,0064,086 24.6%   
Interest Rs m6713,085 21.7%   
Profit before tax Rs m8,4519,310 90.8%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6062,529 63.5%   
Profit after tax Rs m6,7316,781 99.3%  
Gross profit margin %17.022.5 75.6%  
Effective tax rate %19.027.2 70.0%   
Net profit margin %13.511.3 119.4%  
BALANCE SHEET DATA
Current assets Rs m27,06252,623 51.4%   
Current liabilities Rs m15,32452,022 29.5%   
Net working cap to sales %23.51.0 2,346.5%  
Current ratio x1.81.0 174.6%  
Inventory Days Days67120 55.6%  
Debtors Days Days4176 54.2%  
Net fixed assets Rs m12,61085,016 14.8%   
Share capital Rs m239846 28.3%   
"Free" reserves Rs m34,49045,376 76.0%   
Net worth Rs m35,02746,222 75.8%   
Long term debt Rs m1,21241,115 2.9%   
Total assets Rs m54,387142,432 38.2%  
Interest coverage x13.64.0 338.5%   
Debt to equity ratio x00.9 3.9%  
Sales to assets ratio x0.90.4 217.8%   
Return on assets %13.66.9 196.5%  
Return on equity %19.214.7 131.0%  
Return on capital %24.914.2 175.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56314,580 45.0%   
Fx outflow Rs m3,0123,600 83.7%   
Net fx Rs m3,55210,980 32.3%   
CASH FLOW
From Operations Rs m7,2598,942 81.2%  
From Investments Rs m1,864-47,070 -4.0%  
From Financial Activity Rs m-9,27334,174 -27.1%  
Net Cashflow Rs m-150-3,655 4.1%  

Share Holding

Indian Promoters % 66.9 71.5 93.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 7.0 471.5%  
FIIs % 0.0 12.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.8 -  
Shareholders   68,381 26,511 257.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 18, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - STRIDES SHASUN LTD COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS